Increasing awareness and surge in travel vaccine are anticipated to fuel the growth of the global meningococcal vaccines market at a CAGR of 7.3% during the forecast period of 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Meningococcal Vaccines Market” that contains the information from 2023 to 2032.

The meningococcal vaccines market is expected to register a CAGR of 7.3% during the forecast period 2023-2032, to reach USD 6.80 billion by 2032.

MRFR recognizes the following companies as the key players in the global meningococcal vaccines market— Pfizer Inc (US), Novartis AG (Switzerland), Sanofi S.A.(France), Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Ltd (China), Bio-Manguinhos (Brazil).

Market Highlights

The global meningococcal vaccines market is expected to have a market value of USD 6.80 billion by 2032.

Meningococcal vaccinations are designed to protect against infection with Neisseria meningitidis. Vaccines targeting certain meningococcus strains, such as A, B, C, W-135, and Y, are available. In general, the vaccines produce immunity levels of 80 percent to 100 percent for two years, with some requiring booster doses as well. The vaccines might be monovalent, focused on a specific type of meningococcus, or multivalent in nature.  The increased inclusion of meningococcal vaccinations in national immunisation programmes is expected to propel the meningococcal vaccines market forward. Strict regulatory limits and product recalls, on the other hand, are projected to hinder industry growth. However, the stringent regulatory guidelines and product recalls is anticipated to hamper the market growth.

Segment Analysis

The global meningococcal vaccines market is segmented into vaccine type, serotype, end user and region. The vaccine type segment is further segmented into Conjugate, Subcapsular, Polysaccharide. The serotype segment is segmented into MenACWY, MenB/BC, MenC, MenAC, MenA. The end user segment is further segmented into hospitals, research & academic institutes, others

Regional Analysis

The global meningococcal vaccines, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World.

The North America dominated the global meningococcal vaccines market in 2021. this is due to the presence of key players, well-established healthcare infrastructure, favourable government initiatives for the vaccine development and distribution, and an increase in the number of R&D partnerships. According to the National Meningitis Association (NMA), around 600–1,000 people in the US get meningococcal disease each year, with 15% of those deaths due to a lack of awareness of the disease's symptoms. As a result, increased meningitis cases in the US and increased awareness of the disease are likely to positively impact the meningococcal vaccination market.

The meningococcal vaccine market in Europe is being driven by non-profit organizations that provide financing for research projects, healthcare professional training, patient information and support, and demand driven by a significant increase in routine immunization. According to the European Centre for Disease Prevention and Control, invasive meningococcal disease (IMD) is a leading cause of meningitis and septicemia, with an estimated 200,000 cases occurring each year. The disease often progresses rapidly with an 8–15% case-fatality ratio. The condition is most common in young children, followed by adolescence and young adulthood. Certain European countries that are strategizing for a meningococcal vaccination program are boosting the meningococcal vaccine market.

Asia-Pacific is expected to exhibit the highest CAGR during the forecast period of 2022-2030. This is due the increased transmission of meningococcal bacteria has resulted in a significant increase in the number of clinical programs for the effective development of meningococcal vaccines due to unpredictable occurrences across different age groups and countries, which has bolstered the Asia-Pacific meningococcal vaccines market.

The Rest of the World comprises the Middle East, Africa, and Latin America. The market in rest of the world region is predicted to register a strong CAGR of 10.67% from 2022 to 2030. Meningococcal meningitis is found worldwide, but the disease has the highest prevalence in Africa. Meningococcal meningitis is associated with a high mortality rate of up to 50% when untreated. Furthermore, high prevalence of meningococcal disease in the African region is on the rise. This led to the high demand for vaccines, further influencing the growth of the meningococcal vaccines market

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Meningococcal Vaccines Market Research Report

Key Findings of the Study

• The global meningococcal vaccines market is estimated to reach USD 6.80 billion by 2032 at a CAGR of 7.3% during the assessment period.


• North America accounted for the largest share in 2021. This is due to the presence of key players, well-established healthcare infrastructure, favorable government initiatives for the vaccine development and distribution, and an increase in the number of R&D partnerships in the region.


• Based on vaccine type, the conjugate segment accounted for the largest market share in 2021. This is due to its key advantages, such as long-lasting immunity and its ability to induce herd immunity.


• By Serotype, the MenACWY segment accounted for the largest market share in 2021. This is due to it protects against four different strains of meningococcal bacteria (types A, C, W, and Y). 


• Based on end user, the hospital segment accounted for the largest market share in 2021. This due to the rising demand for vaccines and the growing prevalence and incidence of the meningococcal disease


• Some of the key players operating in the meningococcal vaccines market are Pfizer Inc (US), Novartis AG (Switzerland), Sanofi S.A.(France), Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Ltd (China), Bio-Manguinhos (Brazil).